http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114470039-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b88ef96f433aa8b0652fe0f5ca4d5ac2
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-331
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-284
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-575
filingDate 2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32ff01ebb45e962807d730eaadb615dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4013384f94acda7bd664e3728247e21f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb0cb74f53c56b72a92aa277d6aed4b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4d10bcfd72e810b2d00b60a5d9e6f5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d0e747b2cfaf28b067a94741fb728ed
publicationDate 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-114470039-A
titleOfInvention A kind of traditional Chinese medicine composition for adjuvant treatment of primary insomnia
abstract The invention provides a traditional Chinese medicine composition for auxiliary treatment of primary insomnia, a traditional Chinese medicine composition for auxiliary treatment of primary insomnia, which is characterized in that, in parts by weight, it comprises: 40-60 parts of Poria, 40-60 parts of Atractylodes Rhizoma 60 servings, Angelica 30-50 servings, Angelica 15-35 servings, Magnolia 12-16 servings. The traditional Chinese medicine composition provided by the invention can achieve the function of calming the nerves. By taking the composition orally, the uncomfortable symptoms caused by primary insomnia can be effectively relieved, and the combination of intravenous infusion of dexmedetomidine and/or acupoint stimulation and other means can effectively relieve the discomfort caused by primary insomnia. Effective treatment of primary insomnia.
priorityDate 2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394675
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536562
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311068

Total number of triples: 26.